ecropolis

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series | FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro

By Dickson Despommier —
The sign reads: “Wet Paint. Please Do Not Touch”. Yet despite this simple warning, when we encounter one, what is the first thing we do? The next thing we look for is a rag to wipe off the tell-tale evidence of our misguided skepticism. We even have an expression for such events: “Curiosity killed the cat but satisfaction brought it back”.

The feasibility of convalescent plasma therapy in severe COVID-19 patients | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up

Clinical Reports: Characteristics of Infected Children in Hubei, Case-fatality rate and characteristics of patients in Italy, functional exhaustion of antiviral lymphocytes
Antiviral Therapeutics: FDA approval for plasma treatment, convalescent sera option

Clinical: China retrospectives |
Therapies: Lopinavir-Ritonavir, Hydroxychoroquine and Azithromycin trials | Epidemiology: Non-pharmaceutical interventions, cryptic transmission | Environmental: Aerosol and surface stability